Biohaven Ltd. BHVN

BHVN Company Overview

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for neurological, neuropsychiatric, immunologic, and rare diseases. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on treatments targeting central nervous system disorders and immune-mediated conditions. Its core revenue and valuation drivers are tied to its late-stage and pipeline therapeutic candidates, strategic licensing arrangements, and intellectual property portfolio. Biohaven is particularly recognized for its work in calcitonin gene-related peptide (CGRP) therapeutics and glutamate modulation technologies.

The company traces its origins to Biohaven Pharmaceutical Holding Company Ltd., founded in 2013 by Dr. Vlad Coric and other biotechnology executives and researchers. In 2022, Pfizer Inc. acquired Biohaven’s commercial-stage CGRP migraine business, including approved migraine assets, while the remaining development-stage businesses continued as Biohaven Ltd., which now trades on the New York Stock Exchange under the ticker BHVN. Following the transaction, the company repositioned itself as a pipeline-focused biotechnology company with multiple investigational programs spanning neuroscience, immunology, oncology-supportive care, and rare disorders.